Favorable Press Coverage Very Unlikely to Impact Ironwood Pharmaceuticals (NASDAQ:IRWD) Share Price
News stories about Ironwood Pharmaceuticals (NASDAQ:IRWD) have trended positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a news impact score of 0.39 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 21 out of 100, indicating that recent media coverage is very unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Mizuho Reiterates Buy Rating for Ironwood Pharmaceuticals, Inc. (IRWD) (americanbankingnews.com)
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Cut to Sell at BidaskClub (americanbankingnews.com)
- Zacks: Brokerages Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Quarterly Sales of $68.48 Million (americanbankingnews.com)
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Sees Significantly Lower Trading Volume (highlightpress.com)
- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Experiences Lighter than Average Trading Volume (highlightpress.com)
Several research analysts recently commented on IRWD shares. BidaskClub upgraded Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Mizuho lifted their price target on Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, July 4th. Cowen and Company set a $20.00 price target on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, April 13th. Wells Fargo & Company set a $19.00 price target on Ironwood Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, July 22nd. Finally, ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $18.00.
Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) traded down 6.31% during mid-day trading on Thursday, reaching $16.64. 2,123,280 shares of the company’s stock traded hands. The stock’s market capitalization is $2.23 billion. Ironwood Pharmaceuticals has a 12-month low of $12.48 and a 12-month high of $19.94. The company’s 50-day moving average price is $18.36 and its 200-day moving average price is $17.14.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Monday, May 8th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.14. The company had revenue of $52.16 million during the quarter, compared to analyst estimates of $69.39 million. Ironwood Pharmaceuticals had a negative return on equity of 195.06% and a negative net margin of 46.49%. The business’s revenue was down 21.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.08) earnings per share. Analysts anticipate that Ironwood Pharmaceuticals will post ($0.91) earnings per share for the current year.
In other Ironwood Pharmaceuticals news, insider Thomas A. Mccourt sold 30,000 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $18.20, for a total transaction of $546,000.00. Following the sale, the insider now directly owns 30,000 shares in the company, valued at approximately $546,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Halley E. Gilbert sold 35,000 shares of the stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $19.75, for a total transaction of $691,250.00. Following the sale, the insider now owns 35,000 shares in the company, valued at $691,250. The disclosure for this sale can be found here. 7.63% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Favorable Press Coverage Very Unlikely to Impact Ironwood Pharmaceuticals (NASDAQ:IRWD) Share Price” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/03/positive-media-coverage-very-unlikely-to-impact-ironwood-pharmaceuticals-nasdaqirwd-share-price-updated-updated-updated.html.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.